Dexamethasone and Dexmedetomidine as Adjuvants to Ropivacaine in Ultrasound-guided Multilevel Thoracic Paravertebral Block for Lobectomy: A Prospective, Randomized, Triple-blind Study

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04763434

Enrollment

Registered

2021-02-21

Start date

2021-03-20

Completion date

2021-08-30

Last updated

2021-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dexamethasone, Dexmedetomidine, Lobectomy, Ropivacaine

Brief summary

The hypothesis is whether perineural dexamethasone and dexmedetomidine prolonged the duration of analgesia as compared with either perineural dexamethasone or perineural dexmedetomidine after TPVB.

Detailed description

Design: A prospective, randomized, controlled study Setting: Single-center university hospital. Participants: The study included 90 patients undergoing lobectomy under general anesthesia. Interventions: The patients were allocated randomly into the following 3 groups: 20 ml mixture of 37.5 mg ropivacaine with 5 mg dexamethasone (RS group) or 1 µg/kg dexmedetomidine (RM group), or with 1 µg/kg dexmedetomidine and 5 mg dexamethasone (RSM group). Ultrasound-guided TPVB was performed at 4 points-T4-5, T5-6, T6-7, and T7-8 of the surgical side; 5 mL of solution were injected at each point. Postoperatively, the PCIA was used as part of multimodal analgesia, and all patients recieve .

Interventions

DRUGdexamethasone; dexmedetomidine; ropivacaine

Ultrasound-guided multilevelTPVB is performed at the end of lobectomy

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

16 Years to 65 Years

Healthy volunteers

Inclusion criteria

ASA physical status I-II grade Undergoing elective lobectomy under general anesthesia. Participants aged from 16-65 years old.

Exclusion criteria

Refusal for TPVB Inability to obtain informed consent Coagulation disorders, neuropathy, or body mass index greater than 40 kg/m2 Pregnancy Infections at the site of injection for the TPVB Allergy to dexamethasone; dexmedetomidine; ropivacaine Clinically significant cardiovascular, pulmonary, renal, or hepatic diseases

Design outcomes

Primary

Measure	Time frame	Description
the duration of analgesia	48 hours after surgery	time from completion of TPVB operation to VAS more than 3

Secondary

Measure	Time frame	Description
total sufentanil consumption	48 hours after surgery	—
VAS	1, 2, 4, 8, 12, 24, 36, and 48 hours after surgery	VAS at rest and during coughing are evaluated by a blinded observer postoperatively
adverse effects	48 hours after surgery	—

Contacts

Primary Contactwen jun yan, doctor

yanwj2008@hotmail.com17361552758

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026